Skye Bioscience, Inc. (SKYE) Stock Score, Valuation & Financial Research

Skye Bioscience, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SKYE

Skye Bioscience, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.57. These figures are a research snapshot, not a buy or sell recommendation.

What Skye Bioscience, Inc. does

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Skye Bioscience is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model is focused on the research and development of proprietary pharmaceutical candidates, specifically targeting G-protein coupled receptors to treat metabolic diseases like obesity, and it relies on raising capital to fund these operations.

Products and services

  • The company's lead drug candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody designed to target the cannabinoid receptor 1 (CB1) for the treatment of obesity and metabolic disorders.

Brands and product families

  • nimacimab — Lead clinical-stage antibody drug candidate targeting CB1 receptors. Source

Customer types

Patients with obesity and metabolic diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company utilizes third-party service providers for clinical trial management, drug substance manufacturing, and other research-related services. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary pipeline focused on CB1 receptor modulation Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises Source
  • Clinical trial failure or regulatory delays Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SKYE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.57
Market capitalization:
6.87M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -50.49M
Free cash flow:
USD -43.07M
Cash:
USD 8.07M
Total debt:
USD 35.7K
EPS:
USD -10.16

What stands out

  • Free cash flow is USD -43.07M, negative for the stored period.
  • The balance sheet shows USD 8.07M of cash versus USD 35.7K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SKYE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SKYE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SKYE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SKYE to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of SKYE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SKYE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.